New agents for Staphylococcus aureus endocarditis

Current Opinion in Infectious Diseases

Volumn 19, Issue 6, 2006, Pages 544-550

  Drees, Marci ^a   Boucher, Helen ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Endocarditis; Staphylococcus aureus; Telavancin; Vancomycin

Indexed keywords

CEFTOBIPROLE; CIPROFLOXACIN; CLINAFLOXACIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NAFCILLIN; ORITAVANCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; BACTERIAL ENDOCARDITIS; ENZYME BLOOD LEVEL; HUMAN; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR DISEASE; VENOUS INTOLERANCE;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33750569802     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328010683e     Document Type: Article

References (74)

1. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41:507-514 [Erratum in Clin Infect Dis 2005; 41:1075-77]. This large retrospective series of native valve endocarditis cases from the USA and four European countries demonstrates worse outcomes among patients with S. aureus infection compared with non-S. aureus endocarditis. The study also is the first to show geographic variation in outcomes, a finding which requires further investigation.
2. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49:2735-2745.
3. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496-503.
4. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82:333-339.
5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317 [Erratum in Clin Infect Dis 2004; 39:1093].
6. Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589-608. This evidence-based review provides guidelines for prevention and treatment of MRSA, including bacteremia and endocarditis as well as infections of skin and soft tissues, bones and joints, respiratory tract and other sites.
7. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066-2072.
8. Crum NF. The emergence of severe, community-acquired methicillin- resistant Staphylococcus aureus infections [Review]. Scand J Infect Dis 2005; 37:651-656. This article provides a nice summary of community-acquired MRSA and reviews 16 cases, only one of which was empirically treated with antibiotics active against MRSA.
9. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24:826-831. An excellent review of therapeutic options for resistant S. aureus and enterococcal infections.
10. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. [See comment]. Clin Infect Dis 2003; 36:53-59.
11. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. [See comment]. Clin Infect Dis 2004; 38:1700-1705.
12. Gentry CA, Rodvold KA, Novak RM, et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990-997.
13. Lin JC, Wu JS, Chang FY. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis with septic embolism of popliteal artery: a case report. J Microbiol Immunol Infect 2000; 33:57-59.
14. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-1231.
15. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402.
16. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-439.
17. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-528.
18. Woods CW, Cheng AC, Fowler VG Jr, et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 38:1188-1191.
19. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-451.
20. Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33:120-125.
21. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. [See comment]. Ann Intern Med 1991; 115:674-680.
22. Dailey CF, leto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:2304-2308.
23. Jacqueline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared with vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002; 46:3706-3711.
24. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3002-3004.
25. Jacqueline C, Navas D, Batard E, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:45-51.
26. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-992.
27. Bassetti M, Di Biagio A, Del Bono V, et al. Successful treatment of methicillinresistant Staphylococcus aureus endocarditis with linezolid. Int J Antimicrob Agents 2004; 24:83-84.
28. Souli M, Pontikis K, Chryssouli Z, et al. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. Eur J Clin Microbiol Infect Dis 2005; 24:760-762.
29. Leung KT, Tong MK, Siu YP, et al. Treatment of vancomycin-intermediate Staphylcoccus aureus endocarditis with linezolid. Scand J Infect Dis 2004; 36 (6-7):483-485.
30. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599-1602. This study assessed clinical outcomes and toxicity in 44 patients treated with linezolid, including 16 patients with MRSA and 18 with hVISA or VISA. Four patients had endocarditis. While outcomes were generally good (73% achieved clinical cure), 64% had definite or probable adverse reactions and 16% had to discontinue therapy.
31. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37 (11-12):946-949.
32. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018-1020.
33. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57:279-287.
34. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections [Review]. Am J Med Sci 2005; 330:102-104.
35. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-208.
36. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels [comment]. Clin Infect Dis 2003; 36:675-676.
37. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a reviewof postmarketing data. Clin Infect Dis 2006; 42:1578-1583. This review of FDA postmarketing adverse event data reports 29 cases of serotonin syndrome due to linezolid. The most frequent associated medication was selective serotonin reuptake inhibitors (SSRIs).
38. Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64:926-927.
39. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003; 47:539-546.
40. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45:454-459.
41. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-2152.
42. Cunha BA, Hamid N, Kessler H, Parchuri S. Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung 2005; 34:442-447.
43. Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005; 34:69-71.
44. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for Staphylococcus aureus bacteremia and endocarditis. N Engl J Med 2006; 355:653-665. This study, the largest comparative trial of S. aureus bacteremia and endocarditis to date, found daptomycin to be noninferior to either an antistaphylococcal penicillin or vancomycin for bacteremia and right-sided endocarditis due to MSSA or MRSA. Daptomycin was well tolerated; while 25% had elevations in creatine phosphokinase, in only three patients did this lead to discontinuation of therapy. High incidence of renal dysfunction was attributed to the addition of gentamicin for the first 4 days of therapy in the comparator group who received vancomycin and/or B-lactam therapy.
45. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
46. Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-5287.
47. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655-656.
48. Vouillamoz J, Entenza JM, Feger C, et al. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide- streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44:1789-1795.
49. Pavie J, Lefort A, Zarrouk V, et al. Efficacies of quinupristin- dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics. Antimicrob Agents Chemother 2002; 46:3061-3064.
50. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775-784.
51. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000; 44:2225-2229.
52. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52:215-227.
53. Sader HS, Jones RN, Stilwell MG, et al. Tigecycline activity tested against 26 474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52:181-186.
54. Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46:2595-2601.
55. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56:470-480. A comprehensive review of the new drug tigecycline.
56. Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022-3027.
57. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101:68-76.
58. Chambers HF, Xiang Q, Liu et al. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group Streptococcus or Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:2742-2746.
59. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41:1662-1667.
60. Entenza JM, Que YA, Vouillamoz J, et al. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother 2001; 45:3076-3083.
61. Berrington AW, Koerner RJ, Perry JD, et al. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol 2001; 291:237-239.
62. Levine DP, Holley HP, Eiseman I, et al. Clinafloxacin for the treatment of bacterial endocarditis. Clin Infect Dis 2004; 38:620-631.
63. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969-974.
64. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-e434. This paper describes the current evidence-based guidelines for the role of echocardiography, treatment and management of complications of endocarditis. Both native and prosthetic valve infection are discussed, as well as differential management of endocarditits in injection drug users (IDUs) vs. non-IDUs. Etiologic agents discussed include staphylococci, streptococci, enterococci, the HACEK organisms, and Gram-negative bacteria.
65. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-380. This study was not completed, but among the 75 patients with catheter-related bloodstream infection who were enrolled, dalbavancin had an 87% success rate compared with 50% for vancomycin. In each group, approximately 42% had S. aureus infection, with 19% in the dalbavancin group having MRSA vs. 32% in the vancomycin group.
66. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-1415. This study compared 2 doses of dalbavancin (on day 1 and day 8) to 14 days of linezolid for complicated SSSI. There was no observed difference in efficacy, though linezolid was found to have a higher rate of adverse events thought secondary to treatment (32.3% vs. 25.4% in dalbavancin-treated patients), with gastrointestinal side effects most common in both treatment arms.
67. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-3050.
68. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-3165.
69. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005; 56:337-343.
70. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862-867. This study compared telavancin with an antistaphylococcal penicillin or vancomycin for complicated SSSI. While overall clinical cure rates were similar, among the microbiologically evaluable population (62% of total), the results suggested that telavancin may perform better than comparator. Only among patients with MRSA, however, were these results statistically significant, with 92% of telavancin-treated patients achieving eradication vs. 68% of comparator-treated patients. Overall adverse event rates were similar (approximately 55% in both groups), but adverse events requiring discontinuation of treatment were twice as common in the telavancin group (6% vs. 3%).
71. Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42:981-983.
72. Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004; 50:95-102.
73. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-4219.
74. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:884-888.